NASDAQ:CNSY Plus Therapeutics Q2 2026 Earnings Results & Report $0.95 +0.18 (+23.32%) Closing price 04:00 PM EasternExtended Trading$0.92 -0.03 (-3.49%) As of 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Plus Therapeutics missed analyst earnings expectations in its Q2 2026 results, released August 14, 2026. The company reported EPS of -$1.31 versus the -$0.96 consensus estimate, while revenue was $411 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 14, 2026TimeAfter Market Closes Plus Therapeutics EPS ResultsActual EPS-$1.31Consensus EPS -$0.96Beat/MissMissed by -$0.35One Year Ago EPSN/APlus Therapeutics Revenue ResultsActual Revenue$411 thousandExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Plus Therapeutics Q2 2026 Earnings FAQ Did Plus Therapeutics beat earnings estimates for Q2 2026? Plus Therapeutics (NASDAQ:CNSY) reported earnings of -$1.31 per share for Q2 2026, missing the consensus estimate of -$0.96. The report was announced on Friday, August 14, 2026. What was Plus Therapeutics' revenue for Q2 2026? Plus Therapeutics reported revenue of $411 thousand for Q2 2026. Plus Therapeutics Earnings HeadlinesCerenome Reports Third Quarter 2026 Financial Results and Business Highlights Featuring REYOBIQ ReSPECT- LM Data and CNSide Commercial and Reimbursement Progress1 hour ago | globenewswire.comCerenome to Review REYOBIQ ReSPECT-LM Data Presented at SNO Conference and Provide CNSide Commercial Update on November 16November 12 at 7:30 AM | globenewswire.comI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 13 at 1:00 AM | Behind the Markets (Ad)Cerenome Appoints Director Ron Andrews as Chief Business OfficerNovember 10 at 7:30 AM | globenewswire.comPlus Therapeutics (NASDAQ:CNSY) Stock Falls 4.1% - Here's What HappenedNovember 7, 2026 | americanbankingnews.comCerenome Secures National In-Network Agreement with Aetna for CNSide®November 4, 2026 | globenewswire.comSee More Plus Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Plus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Plus Therapeutics and other key companies, straight to your email. Email Address About Plus TherapeuticsPlus Therapeutics (NASDAQ:CNSY) is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. Its lead investigational product is Rhenium-186 NanoLiposome (RNL), a proprietary formulation designed to deliver the radioactive isotope rhenium-186 directly to tumors while limiting exposure to surrounding healthy tissue. The company has focused its development programs primarily on central nervous system cancers, including recurrent glioblastoma and leptomeningeal metastases. Plus Therapeutics has evaluated RNL in clinical studies involving localized administration to the tumor or surrounding fluid spaces and has worked to advance the product through regulatory and clinical development activities. Based in Austin, Texas, Plus Therapeutics serves the oncology research and healthcare markets through its drug-development programs and collaborations. The company was formerly known as Cytori Therapeutics before adopting the Plus Therapeutics name. Its leadership has included Marc H. Hedrick, M.D., who has served as president and chief executive officer.View Plus Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCostco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsLightPath Technologies' Record Backlog Highlights a Bigger Defense OpportunityThese 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went ShoppingGolden Dome’s $185 Billion Question: Who Actually Gets Paid? Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
